CEPI will provide up to $25 million to the University of Oxford to complete early development of prototype vaccines against the Jun\u00edn virus, while also looking to improve manufacturing speed and scale-up of ChAdOx technology.\r\nLearnings could be leveraged to inform vaccine design for related viruses from the Arenavirus family, giving the world a head start in rapidly responding to future outbreaks in as little as 100 days.\r\nFirst project to be initiated under CEPI and University of Oxford\u2019s strategic partnership to accelerate global pandemic preparedness efforts.
An estimated 95,000\u2013167,000 inpatients at English National Health Service (NHS) hospitals caught SARS-CoV-2 while in hospital during England\u2019s \u2018second wave\u2019 of COVID-19, between June 2020 and March 2021, reports a study in Nature. The findings reveal the scale of hospital transmissions and highlight contributing factors, such as a limited number of single rooms.
As the COVID-19 pandemic demonstrated, viruses can quickly evolve new ways of evading our immune systems, undermining our efforts to control outbreaks. But a new artificial intelligence (AI) tool developed by researchers at the University of Oxford and Harvard Medical School could help predict new viral variants before they emerge. The findings have been published in the journal Nature.
An academic/industry partnership, based at the NIHR Oxford Health Biomedical Research Centre, is helping companies use experimental medicine approaches to speed up development of new drugs to treat psychiatric disorders.
What we desperately need are new tools to improve malaria control, and this is the first vaccine that can be deployed at scale, that will be affordable, and can be used widely in Africa on a scale of hundreds of millions of doses each year.
Project headed by Oxford University\u2019s Professor Teresa Lambe OBE (Calleva Head of Vaccinology and Immunology, Department of Paediatrics) and co-developer of the Oxford/AstraZeneca COVID-19 vaccine and Paul Klenerman (Sidney Truelove Professor, Nuffield Department of Medicine)
A team of researchers from the University of Oxford has shown for the first time that it is possible to track the progression of Parkinson\u2019s Disease accurately using specially trained machine learning algorithms to analyse data derived from sensor devices worn by patients.
Professor Alan Bernstein has been appointed as the new head of Oxford Global Health, which will bring together and showcase the breadth of global health research across the University of Oxford.
A new study led by the University of Oxford has found that natural evolution of antibiotic resistance genes has maintained resistance in bacteria despite a reduction in the use of antibiotics. The findings demonstrate the importance of understanding the regulatory evolution of resistance genes to strategically combat AMR. The study has been published in the Journal of the International Society for Microbial Ecology (ISME).
Researchers from the Nuffield Department of Clinical Neurosciences at the University of Oxford, along with colleagues at Cambridge University and Barts and the London School of Medicine and Dentistry, have shown the potential of a new gene therapy approach to silence human sensory neurons (nerve cells) as a means of treating persistent pain. Many current drugs for chronic pain are highly addictive, which makes it important to discover new alternatives.
A breakthrough technique developed by University of Oxford researchers could one day provide tailored repairs for those who suffer brain injuries. The researchers demonstrated for the first time that neural cells can be 3D printed to mimic the architecture of the cerebral cortex. These results have been published today in the journal Nature Communications.
The University of Oxford and Harrington Discovery Institute at University Hospitals in Cleveland, Ohio announced the launch of the Oxford-Harrington Rare Disease Centre Therapeutics Accelerator with an official signing event at the University of Oxford. The event was hosted by the Oxford-Harrington Rare Disease Centre (OHC), a partnership established in 2019 between the University of Oxford and Harrington Discovery Institute. Attendance at the signing included leaders from OHC, the University of Oxford, the Harrington family, University Hospitals, and Oxford Science Enterprises.
The launch of a new endoscopy service at the Oxford Experimental Medicine Clinical Research Facility (EMCRF) will enhance the collection of data for research projects at the Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences (NDORMS) and across the University of Oxford.
The highly effective vaccine developed by the University of Oxford and the Serum Institute of India, leveraging Novavax\u2019s adjuvant is critical to reducing over half a million malaria-related deaths annually.
Researchers at the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) have found a protein to block the growth of cancer stem-like cells as a possible treatment for pancreatic cancer.
A study looking at the longer-term impact of COVID-19 has found that nearly a third of patients displayed abnormalities in multiple organs five months after infection, some of which have been shown through previous work to be evidence of tissue damage.
Young people\u2019s mental health deteriorated during COVID-19, with higher levels of depression and social, emotional and behavioural difficulties than before the pandemic hit, a comprehensive new study has shown.
![\"Woman](\"https://www.medsci.ox.ac.uk/news/cepi-and-university-of-oxford-advance-vaccine-work-against-potentially-deadly-arenaviruses/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n